Yasaman Taheri, H. Suleria, N. Martins, O. Sytar, Ahmet Beyatli, B. Yeskaliyeva, G. Seitimova, B. Salehi, Prabhakar Semwal, Sakshi Painuli, Anuj Kumar, E. Azzini, M. Martorell, W. Setzer, A. Maroyi, Javad Sharifi‐Rad
tlooto Summary
New insights are provided on myricetin preclinical pharmacological activities, and role in selected clinical trials, which provide new insights on the neuroprotective activity of this flavonoid.
Abstract
Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.
Citation format
TAHERI, Yasaman, et al. Myricetin bioactive effects: Moving from preclinical evidence to potential clinical applications. BMC Complementary Medicine and Therapies, 2020, 20.